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Background: To compare the dosimetric differences among fixed field intensity-modulated radiation therapy
(IMRT), single-arc volumetric-modulated arc therapy (SA-VMAT) and double-arc volumetric-modulated arc therapy
(DA-VMAT) plans in rectal cancer.
Method: Fifteen patients with rectal cancer previously treated with IMRT in our institution were selected for this
study. For each patient, three plans were generated with the planning CT scan: one using a fixed beam IMRT, and
two plans using the VMAT technique: SA-VMAT and DA-VMAT. Dose prescription to the PTV was 50 Gy in 2 Gy per
fraction. Dose volume histograms (DVH) for the target volume and the organs at risk (small bowel, bladder, femoral
heads and healthy tissue) were compared for these different techniques. Monitor units (MU) and delivery treatment
time were also reported.
Results: DA-VMAT achieved the highest minimum planning target volume (PTV) dose and the lowest maximal dose,
resulting in the most homogeneous PTV dose distribution. DA-VMAT also yielded the best CI, although the difference was
not statistically significant. Between SA-VMAT and IMRT, the target dose coverage was largely comparable; however,
SA-VMAT was able to achieve a better V95 and V107. VMAT showed to be inferior to IMRT in terms of organ at risk
sparing, especially for the small bowel. Compared with IMRT, DA-VMAT increased the V15 of small bowel nearly 55 cc.
The MU and treatment delivery time were significantly reduced by the use of VMAT techniques.
Conclusion: VMAT is a new radiation technique that combines the ability to achieve highly conformal dose distributions
with highly efficient treatment delivery. Considering the inferior role of normal tissue sparing, especially for small bowel,
VMAT need further investigation in rectal cancer treatment.Background
Rectal cancer radiotherapy is a complex problem be-
cause of the shape of target volumes and the need of
minimizing the involvement of organs at risk (OAR)
such as small bowel, bladder and femur heads [1]. Lots
of planning studies have demonstrated the advantages
of Intensity-modulated radiation therapy (IMRT) in
target coverage and normal tissue sparing over three-
dimensional conformal radiotherapy (3D-CRT) for rec-
tal cancer patients [2-4]. However, drawbacks of the
IMRT technique have also been reported. The pro-
longed delivery time per fraction may worsen the accur-
acy of treatment because of increased intra-fractional
patient motion. In addition, more monitor units (MU) and
a bigger volume of normal tissue exposed to lower radi-
ation dose would increase the possibility of radiation-
induced secondary malignancies [5,6].* Correspondence: fdwyy1981@hotmail.com
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unless otherwise stated.Volumetric-modulated arc therapy (VMAT) is a tech-
nique enabling an intensity-modulated dose to be delivered
during a continuous gantry rotation. For the dynamically
moving multileaf collimator (MLC), variable dose rate and
gantry rotation speed during the rotation, VMAT could
achieve highly conformal dose distributions and is essen-
tially an alternative form of IMRT [7,8]. Moreover, the im-
provement in treatment delivery efficiency and the
reduction in MU usage of this novel technique could over-
come the reported shortages of IMRT [9].
Most of the planning studies in various tumor sites have
compared VMAT with either fixed field IMRT or 3D-CRT
techniques [10-13]. However, the efficacy of VMAT may be
organ-site dependent. In rectal cancer, VMAT has clear
superiority over 3D-CRT with regard to improving dose
conformity and OAR sparing [14,15]. However, the distinc-
tion between VMAT and fixed field IMRT is not well docu-
mented. To our knowledge, there is only one planning study
comparing IMRT and VMAT in rectal cancer until now.
This study was done by Cilla et al. [16] in Italy. However,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(DA)-VMAT for rectal cancer patients was not compared in
Cilla’s study. In present study, we compared the dosimetric
parameters among fixed field IMRT, SA-VMAT and DA-
VMAT for rectal cancer patients and evaluated the efficacy
of VMAT technique in rectal cancer treatment.
Methods
Patient and simulation
Fifteen patients with pathologically proven rectal cancer in
locally advanced stage, subjected to radical postoperative
radiotherapy were selected for this study. There were nine
males and six females. The median age of these patients
was 59 (range, 38–79). The research protocol was reviewed
and approved by Ethics Committee of General Hospital of
Ningxia Medical University. All patients were simulated in
prone position with full bladder and immobilized with
Belly-board to dislocate anteriorly as much as possible in-
testinal loops of small bowel. Computed tomography (CT)
scans were acquired with 3-mm slice thickness through the
L1 vertebral body to 5 cm below the perineum.
Target volume definition
Target volumes were outlined on the planning CT scan
by the treating radiation oncologist. The clinical target vol-
ume (CTV) was delineated according to published con-
sensus guidelines [17]. The planning target volume (PTV)
was defined with margins around the CTV of: 0.5 cm lat-
eral, 1 cm superior-inferior and 0.8 cm anterior-posterior.
Bladder, small bowel and femur heads were contoured as
OAR. The small bowel loops was outlined 3 cm above and
below the PTV, and the bladder and femur heads were
fully outlined. In addition, the healthy tissue was defined
as the patient’s volume included in the CT dataset minus
the PTV volume.
Dose constraints for PTV and normal tissue
Dose prescription to the PTV was 50 Gy in 2 Gy per
fraction. Dose constraints for the PTV were as follows;
(1) ≥ 98% of the PTV receives ≥ 93% of the prescribed
dose, (2) ≤ 10% of the PTV receives ≥ 105% of the pre-
scribed dose, (3) ≤ 5% of the PTV receives ≥ 110% of the
prescribed dose. (4) None of the PTV receives ≥ 115% of
the prescribed dose. For OAR, small bowel V35 Gy <
180 cc, V40 Gy < 100 cc, V45 Gy < 65 cc and no small
bowel volume should receive 50 Gy; bladder D40% <
40 Gy, D15% < 45 Gy and no bladder volume should re-
ceive 50 Gy; femur heads D40% < 40 Gy, D25% < 45 Gy
and no femur heads should receive 50 Gy.
Planning techniques
Three sets of plans, IMRT, SA-VMAT, and DA-VMAT,
were created on the Eclipse Treatment Planning System
(Version 11.0; Varian Medical Systems), and calculatedusing the Anisotropic Analytical Algorithm, using a 2.5 mm
calculation grid, a tissue heterogeneity correction was ap-
plied. The same dose constraint parameters of PTV and
normal tissue were used for IMRTand VMAT planning.
IMRT planning: IMRT plans were optimised with Direct
Machine Parameter Optimization (DMPO) approach using
seven coplanar beams (0, 50,100,150, 210, 260 and 310)
with a dose rate of 400MU/min and beam energy of 6-MV
photons. The maximal number of segments was set to 100
with a minimal number of MU per segment equal to 3.
VMAT planning: VMAT plans were calculated using
6-MV photons with a maximum variable dose rate of
600MU/min. Single-arc corresponded to a single 360°
rotation and double-arc to two coplanars arcs of 360°
sharing the same isocenter and optimised independently.
These two arcs were delivered with opposite rotation
(clock and counter-clock) and so minimize the off-
treatment between the two beams time about 25 seconds.
For SA-VMAT, field size and collimator rotation were
determined by the automatic tool from Eclipse to en-
compass the PTV. We controlled that the collimator was
always rotated to a value different from zero in order to
avoid tongue and groove effect. For DA-VMAT, the first
arc was similar to the one defined in the single-arc process
except for the rotation of the collimator, which was 360
minus X for the second arc (X corresponded to the rota-
tion of the collimator of the first arc).
Plan evaluation and comparison
Dosimetric parameters to analyze target coverage and
dose distribution in the PTV are as follows; (1) mean
dose, (2) Vn Gy, percentage of the volume receiving ra-
diation ≥ n Gy, (3) D98%, minimum dose to 98% of the
PTV, (4) D2%, maximum dose to 2% of the PTV, (5)
conformality index (CI) defined as the volume encom-
passed by the 95% isodose divided by the PTV volume.
For OAR, the analysis included the mean dose, the max-
imum dose expressed as D2% and a set of appropriate
Vn Gy and Dn values. For healthy tissue, we detailed
the volume of the body minus PTV receiving low doses
(V5, V10, and V20 Gy). The number of MU per fraction
required for each plan and the treatment delivery time
(from beam-on to beam-off ) was reported.
Statistical analysis
To appraise the difference between the techniques,
Wilcoxon non-parametric two-sample test was applied.
Data were considered statistically significant at p < 0.05.
Results
PTV volumes, target coverage, conformity, and dose
homogeneity
The median of the PTV volume outlined in the 15 patients
was 1317.2 cc (range, 1048.4–1587.3). The IMRT, SA-
Table 1 Dosimetric parameters comparison among IMRT, SA-VMAT and DA-VMAT technique for PTV
(mean ± standard deviation)
IMRT SA-VMAT DA-VMAT P (IMRT vs SA-VMAT) P (IMRT vs DA-VMAT)
Dmean (Gy) 52.0 ± 0.2 52.0 ± 0.4 51.6 ± 0.2 0.167 0.001
D2% (Gy) 54.1 ± 0.2 54.0 ± 0.8 53.1 ± 0.3 0.366 0.001
D98% (Gy) 49.2 ± 0.3 49.3 ± 0.2 49.5 ± 0.2 0.230 0.015
V95 (%) 99.6 ± 0.3 99.9 ± 0.1 99.9 ± 0.1 0.001 0.001
V107 (%) 10.2 ± 5.1 5.3 ± 3.9 0.6 ± 0.4 0.017 0.001
CI 1.23 ± 0.05 1.28 ± 0.07 1.21 ± 0.07 0.006 0.305
MU 499.0 ± 41.6 418.5 ± 41.9 438.8 ± 31.7 0.001 0.001
Treatment time (min) 8.0 ± 0.7 1.5 ± 0.2 3.0 ± 0.3 0.001 0.001
IMRT: intensity modulated radiotherapy, SA-VMAT: single-arc volumetric modulated arc therapy, DA-VMAT: double-arc volumetric modulated arc therapy,
PTV: Planning Target Volume, CI: conformity index, MU: monitor units.
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ments for the PTV in all cases. Dosimetric parameters for
the PTV in these three plans were listed and compared in
Table 1. DA-VMAT achieved the highest minimum PTV
dose and the lowest maximal dose, resulting in the mostFigure 1 Representation of isodose distribution in axial, coronal and
(the second line). IMRT: intensity modulated radiotherapy, DA-VMAT: doubhomogeneous PTV dose distribution. DA-VMAT also
yielded the best CI, although the difference was not statisti-
cally significant. Between SA-VMAT and IMRT, the target
dose coverage was largely comparable; however, SA-VMAT
was able to achieve a better V95 and V107. Dosesagittal views for fixed IMRT (the first line) and DA-VMAT
le-arc volumetric modulated arc therapy.
Figure 2 Dose-volume histograms for PTV of an individual patient in present study. IMRT: intensity modulated radiotherapy, DA-VMAT:
double-arc volumetric modulated arc therapy.
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shown in Figures 1 and 2.
OAR
Table 2 shows the dosimetric parameters of the OAR in-
cluding the small bowel, bladder, femur heads and healthy
tissue. For small bowels, no sparing effort was devoted to
this organ. The DVH parameters, Dmean, D2%, V15 and
V30, were increased when use VMAT technique. For blad-
der, planning objectives were met by all techniques and no
relevant difference was observed between DA-VMAT and
IMRT, except the maximal dose. In addition, SA-VMAT
increased the Dmean, V40 and V50 of bladder, when com-
pared with IMRT. Concerning femurs heads, SA-VMATTable 2 Dosimetric parameters comparison for OAR (mean ± s
IMRT SA-VMAT
Small bowel Dmean (Gy) 12.1 ± 8.0 15.5 ± 7.7
D2% (Gy) 35.7 ± 12.1 40.0 ± 10.2
V15 (cc) 132.0 ± 110.2 185.8 ± 130.0
V30 (cc) 48.8 ± 20.0 77.5 ± 21.0
Bladder Dmean (Gy) 39.0 ± 3.3 42.2 ± 4.0
D2% (Gy) 52.9 ± 0.6 53.2 ± 0.7
V30 (cc) 437.1 ± 156.5 479.4 ± 176.5
V40 (cc) 281.9 ± 118.9 366.2 ± 155.8
V50 (cc) 112.0 ± 55.6 185.7 ± 107.4
Femur heads Dmean (Gy) 19.9 ± 4.1 23.2 ± 3.4
D10% (Gy) 28.2 ± 5.5 29.6 ± 4.3
Healthy tissues V5 (cc) 9454.9 ± 1999.3 9827.4 ± 2153.3
V10 (cc) 7833.9 ± 1591.8 8167.6 ± 1789.4
V20 (cc) 5224.2 ± 1084.5 4721.8 ± 884.3
OAR: organ at risk, IMRT: intensity modulated radiotherapy, SA-VMAT: single-arc vol
arc therapy.and DA-VMAT both showed a significant increase in
mean dose and D10. For healthy tissue, although V20 was
significantly lower for VMAT than for IMRT, V5 and V10
were found to be significantly larger for VMAT with re-
spect to IMRT. DVH of normal tissue for a typical patient
are shown in Figures 3 and 4.MU and treatment delivery time
The MU was significantly reduced by the use of VMAT.
The lower MU combining with less beam mode-up proce-
dures resulted in a much shorter treatment time with
VMAT. Compared to a delivery in 8 min for IMRT, treat-
ment delivery time with VMAT was definitely shorter andtandard deviation)
DA-VMAT P (IMRT vs SA-VMAT) P (IMRT vs DA-VMAT)
15.3 ± 7.6 0.001 0.002
39.6 ± 10.0 0.005 0.009
186.4 ± 128.8 0.004 0.005
78.8 ± 21.5 0.001 0.002
40.0 ± 3.6 0.001 0.074
52.4 ± 0.5 0.132 0.005
463.2 ± 191.2 0.061 0.460
321.1 ± 167.1 0.002 0.140
151.1 ± 115.6 0.001 0.112
24.3 ± 2.8 0.025 0.012
31.5 ± 4.1 0.173 0.047
9815.3 ± 2142.0 0.001 0.001
8331.8 ± 1733.7 0.013 0.001
4750.7 ± 876.5 0.002 0.005
umetric modulated arc therapy, DA-VMAT: double-arc volumetric modulated
Figure 3 Dose-volume histograms for small bowel and bladder of an individual patient in present study. IMRT: intensity modulated
radiotherapy, DA-VMAT: double-arc volumetric modulated arc therapy.
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respectively (Table 1).
Discussion
Arc therapy was initially reported in rectal cancer by
Duthoy et al. [14] in a planning study comparing 3D-CRT
and Intensity-modulated arc therapy (IMAT). They found
IMAT plans were deliverable within a 5–10-minute time
slot, and resulted in a lower dose to the small bowel than
3D-CRT plans, without creating significant underdosages
in the PTV. Richetti et al. [15] reported on their technical
and clinical experience of 25 patients with locally advanced
rectal cancer treated with VMATand performed a planningFigure 4 Dose-volume histograms for femur head and healthy tissue
radiotherapy, DA-VMAT: double-arc volumetric modulated arc therapy.comparison with a matched cohort of patients who under-
went conventional conformal radiotherapy. VMAT im-
proved conformality of doses, presented similar target
coverage with lower maximum doses, significant sparing of
femur heads and significant reduction of integral and mean
dose to healthy tissue. Acute toxicity was limited to Grade
1–2 diarrhea in 40% and Grade 3 in 8% of VMAT patients,
45% and 5% of conventional conformal radiotherapy
patients, compatible with known effects of concomitant
chemotherapy. To our knowledge, there is only one plan-
ning study comparing IMRT and VMAT in rectal cancer
until now. This study was done by Cilla et al. [16] in Italy.
VMAT had the highest level of conformality, but the doseof an individual patient in present study. IMRT: intensity modulated
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IMRT and 3D-CRT were found in their study. With respect
to the V15 objective, they found small bowel irradiation to
be significantly reduced to 171.2 cc with VMAT, compared
with 199.5 cc and 227.4 cc with IMRT and 3D-CRT,
respectively.
In present study, we evaluated the feasibility and effi-
ciency of IMRT, SA-VMAT and DA-VMAT for the treat-
ment of rectal cancer. The major advantage of using the
VMAT technique is the significant reduction in treat-
ment times with its potential advantages in lower MU.
This improvement is mainly from the elimination of all
the non-beam-on times, such as MLC movements to
realize the various segments of IMRT beams or gantry
motion to reach the fixed position. The reduction of
treatment delivery time is clinically relevant considering
the patient comfort and infra-fraction motion. The
higher delivery efficiency also allowed for more time for
image-guided radiotherapy to further reduce the treat-
ment margin and toxicity [18].
Although there is a clear advantage of VMAT in terms
of faster delivery and lower MU, this needs to be bal-
anced with the dosimetric differences. Compared with
IMRT, DA-VMAT provided better coverage of target but
not the normal tissue sparing, especially for the small
bowel, which was different from the conclusion made in
Cilla’s study. The first reason of the difference is that the
healthy tissue which received dose below 20 Gy was in-
creased when using VMAT technique in present ana-
lysis. Although this finding was supported by other
dosimetric studies [19-21], the low dose bath may en-
large the V15 of small bowel. Another reason of the dif-
ferent small bowel sparing effect is that we enrolled
postoperative rectal cancer patients in present study. It
was shown that patients who receive postoperative radio-
therapy have a larger portion of small bowel in the pelvis
[22]. Lastly, we followed the dose–volume constraints of
RTOG0822 protocol and did not make lower dose-volume
constraint in the planning procedure, which may contrib-
ute to the enlargement of V15 for small bowel.
Conclusion
VMAT is a new radiation technique that combines the abil-
ity to achieve highly conformal dose distributions with highly
efficient treatment delivery. Considering the inferior role of
normal tissue sparing, especially for small bowel, VMAT
need further investigation in rectal cancer treatment.
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